Meeting of the National Advisory Council for Healthcare Research and Quality, 30746-30747 [2023-10140]

Download as PDF 30746 Federal Register / Vol. 88, No. 92 / Friday, May 12, 2023 / Notices committee).11 The Audit Division Recommendation Report and proposed Final Audit Report of the Commission will be circulated to the Commission for a vote on a one-week tally. If any commissioner objects during the tally vote, the Audit Division Recommendation Report shall be placed on the Commission’s next open session agenda. lotter on DSK11XQN23PROD with NOTICES1 II. Final Audit Report of the Commission The Final Audit Report of the Commission will include all findings receiving four or more affirmative votes of the commissioners. If no findings are approved, the Final Audit Report of the Commission shall so state. Any proposed audit finding that is rejected by four or more votes will not be included in the Final Audit Report of the Commission. Any proposed audit finding the disposition of which does not receive four or more votes will be included in the Final Audit Report of the Commission under the heading ‘‘Issues Not Agreed Upon by a Majority of the Commission.’’ Any commissioner may issue a statement describing the reasons for their vote on any recommendation made by the Audit staff. Any such statement of reasons shall be made part of the file. and documents upon which commissioners relied. IV. Potential Enforcement Within 30 calendar days of the adoption of the Final Audit Report of the Commission, Audit staff will assess whether any Commission-approved audit findings meet Commission approved thresholds for referral to one of the Commission’s enforcement processes in OGC, ADRO, or AF. Such referrals are considered ‘‘information ascertained in the ordinary course of the Commission’s supervisory responsibilities.’’ 52 U.S.C. 30109(a)(2). To the extent the committee took the recommended corrective action as set forth in Section I.E., the Commission may reduce the civil penalty in an OGC enforcement action. To receive this benefit, the committee must have taken the recommended corrective action within 30 calendar days of receipt of the Exit Conference Report, or within 30 calendar days following the resolution of a dispute over a recommended corrective action, whichever occurs later. On behalf of the Commission. Dara S. Lindenbaum, Chair, Federal Election Commission. [FR Doc. 2023–10110 Filed 5–11–23; 8:45 am] III. Publication of the Audit File Within 30 calendar days of the conclusion of the audit by adoption of a Final Audit Report of the Commission, the Commission will publish the audit file on its website. The Commission will disclose the following audit materials as a matter of regular practice, subject to redactions, as necessary, for confidentiality under 52 U.S.C. 30109 and applicable privileges: (1) the Exit Conference Report and accompanying OGC legal analysis, (2) the Audit Division Recommendation Report, (3) memoranda requesting compulsory process, (4) the Final Audit Report of the Commission, (5) committee responses, including attached declarations and affidavits but not including any financial materials, (6) the committee request for an Audit Hearing, (7) the transcript of the Audit Hearing, (8) Vote Certifications, (9) Statements of any commissioners, and (10) any other non-financial materials BILLING CODE 6715–01–P 11 As used here and in Section III, below, ‘‘nonfinancial materials’’ include, but are not limited to, public communications described in 11 CFR 100.26 and solicitations for contributions. ‘‘Financial materials’’ include, but are not limited to, bank records, committee databases and spreadsheets, cancelled checks, loan documentation, credit card merchant statements, invoices, contributor check copies, credit card receipts, signed contracts, payroll journals, and deposit batches. FOR FURTHER INFORMATION CONTACT: VerDate Sep<11>2014 19:11 May 11, 2023 Jkt 259001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality Meeting of the National Advisory Council for Healthcare Research and Quality Agency for Healthcare Research and Quality (AHRQ). ACTION: Notice of public meeting. AGENCY: This notice announces a meeting of the National Advisory Council for Healthcare Research and Quality. SUMMARY: The meeting will be held on Wednesday, July 12, 2023, from 11:15 a.m. to 3:30 p.m. ADDRESSES: The meeting will be held virtually. DATES: Jaime Zimmerman, Designated Management Official, at the Agency for Healthcare Research and Quality, 5600 Fishers Lane, Mail Stop 06E37A, Rockville, Maryland 20857, (301) 427– 1456. For press-related information, please contact Bruce Seeman at (301) PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 427–1998 or Bruce.Seeman@ AHRQ.hhs.gov. Closed captioning will be provided during the meeting. If another reasonable accommodation for a disability is needed, please contact the Food and Drug Administration (FDA) Office of Equal Employment Opportunity and Diversity Management on (301) 827–4840, no later than Wednesday, May 31, 2023. The agenda, roster, and minutes will be available from Jenny Griffith, Committee Management Officer, Agency for Healthcare Research and Quality, 5600 Fishers Lane, Rockville, Maryland 20857. Jenny Griffith’s phone number is (240) 446–6799. SUPPLEMENTARY INFORMATION: I. Purpose In accordance with the Federal Advisory Committee Act, this notice announces a meeting of the National Advisory Council for Healthcare Research and Quality (the Council). 5 U.S.C. 1009. The Council is authorized by section 941 of the Public Health Service Act, 42 U.S.C. 299c. In accordance with its statutory mandate, the Council is to advise the Secretary of the Department of Health and Human Services and the Director of AHRQ on matters related to AHRQ’s conduct of its mission including providing guidance on (A) priorities for health care research, (B) the field of health care research including training needs and information dissemination on health care quality and (C) the role of the Agency in light of private sector activity and opportunities for public private partnerships. The Council is composed of members of the public, appointed by the Secretary, and Federal ex-officio members specified in the authorizing legislation. II. Agenda On Wednesday, July 12, 2023, NAC members will meet to conduct preparatory work prior to convening the Council meeting at 11:15 a.m., with the call to order by the Council Chair, an introduction of NAC members, and approval of previous Council summary notes. The NAC members will then receive an update from the AHRQ Director. The agenda will also include an update on AHRQ’s aging initiatives and a discussion of consumer experience measurements. The meeting is open to the public and will adjourn at 3:30 p.m. For information regarding how to access the meeting as well as other meeting details, including information on how to make a public comment, please go to https:// www.ahrq.gov/news/events/nac/. The E:\FR\FM\12MYN1.SGM 12MYN1 Federal Register / Vol. 88, No. 92 / Friday, May 12, 2023 / Notices final agenda will be available on the AHRQ website no later than Wednesday, June 28, 2023. Dated: May 8, 2023. Marquita Cullom, Associate Director. [FR Doc. 2023–10140 Filed 5–11–23; 8:45 am] BILLING CODE 4160–90–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Toxic Substances and Disease Registry [30Day-23–0063] lotter on DSK11XQN23PROD with NOTICES1 Agency Forms Undergoing Paperwork Reduction Act Review In accordance with the Paperwork Reduction Act of 1995, the Agency for Toxic Substances and Disease Registry (ATSDR) has submitted the information collection request titled ‘‘Human Health Effects of Drinking Water Exposures to Per- and Polyfluoroalkyl Substances (PFAS): A Multi-site Cross-sectional Study (The Multi-site Study)’’ to the Office of Management and Budget (OMB) for review and approval. ATSDR previously published a ‘‘Proposed Data Collection Submitted for Public Comment and Recommendations’’ notice on January 11, 2023, to obtain comments from the public and affected agencies ATSDR did not receive comments related to the previous notice. This notice serves to allow an additional 30 days for public and affected agency comments. ATSDR will accept all comments for this proposed information collection project. The Office of Management and Budget is particularly interested in comments that: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including, through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and VerDate Sep<11>2014 19:11 May 11, 2023 Jkt 259001 (e) Assess information collection costs. To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570. Comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/ do/PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202) 395–5806. Provide written comments within 30 days of notice publication. Proposed Project Human Health Effects of Drinking Water Exposures to Per- and Polyfluoroalkyl Substances (PFAS): A Multi-site Cross-sectional Study (The Multi-site Study) (OMB Control No. 0923–0063, Exp. Date 05/31/2023)– Revision—Agency for Toxic Substances and Disease Registry (ATSDR). Background and Brief Description The Agency for Toxic Substances and Disease Registry (ATSDR) is requesting a three-year Revision of the Paperwork Reduction Act (PRA) Information Collection Request (ICR) titled ‘‘Human Health Effects of Drinking Water Exposures to Per- and Polyfluoroalkyl Substances (PFAS): A Multi-site Crosssectional Study (The Multi-site Study)’’ (OMB Control No. 0923–0063, Exp. Date 05/31/2023). Per- and polyfluoroalkyl substances (PFAS) are a family of chemicals used in industrial applications and consumer products. PFAS contamination of drinking water is widespread in the U.S. Some estimates indicate that at least sixty million residents were served by 66 public water supplies that had at least one sample at or above the U.S. Environmental Protection Agency (EPA) Lifetime Health Advisory for perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) (individually or combined), which is 70 nanograms per liter (ng/L) of water. Industrial facilities that manufacture or use PFAS have contaminated drinking water in surrounding communities in several states. In addition, PFOS, PFOA, perfluorohexane sulfonic acid (PFHxS) and other PFAS chemicals are constituents in aqueous film-forming foam (AFFF), used to extinguish PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 30747 flammable liquid fires. The use of AFFF at military bases and other sites may have resulted in the migration of PFAS chemicals through soils to ground water and/or surface water sources of drinking water for the bases and/or surrounding communities around the country. In response to growing awareness of the extent of PFAS contamination across the U.S., the section 316(a) of the 2018 National Defense Authorization Act (Pub. L. 115–91), as amended by section 315 of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Pub. L. 115–232), first authorized and appropriated funds for ATSDR to conduct this study on the human health effects of PFAS contamination in drinking water. The existence of widespread contamination at many sites across the U.S. makes this a paramount effort in addressing the health effects of exposures to PFAS from contaminated drinking water. Currently, the study is funded through section 337 of the William M. (Mac) Thornberry National Defense Authorization Act for fiscal years 2019 through 2023 (Pub. L. 116–283). The Multi-site Study builds on research methods and activities developed for the proof-of-concept study at the Pease International Tradeport in Portsmouth, New Hampshire (the Pease Study) (OMB Control No. 0923–0061; Discontinued 08/31/2022). These methods and activities included developing data management systems and community engagement materials, modifying the childhood neurobehavioral test battery, adjusting blood collection volume, and modifying data collection materials such as the childhood questionnaire and medical records abstraction forms. ATSDR is conducting this cooperative research program under Notice of Funding Opportunity (NOFO) No. CDC– RFA–TS–19–002, titled ‘‘Multi-site Study of the Health Implications of Exposure to PFAS-Contaminated Drinking Water.’’ The seven research recipients are University of Colorado School of Public Health, Michigan State Department of Health and Human Services, Pennsylvania Department of Health and RTI International, Rutgers School of Public Health, Silent Spring Institute, SUNY at Albany and the New York State Department of Health, and the University of California at Irvine. Under the cooperative agreement, each recipient proposed candidate study sites at communities whose drinking water was impacted by AFFF use or by industrial PFAS releases. Site selection considered the documented levels of PFAS drinking water concentrations. The aim was to include sites so that a E:\FR\FM\12MYN1.SGM 12MYN1

Agencies

[Federal Register Volume 88, Number 92 (Friday, May 12, 2023)]
[Notices]
[Pages 30746-30747]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-10140]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality


Meeting of the National Advisory Council for Healthcare Research 
and Quality

AGENCY: Agency for Healthcare Research and Quality (AHRQ).

ACTION: Notice of public meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces a meeting of the National Advisory 
Council for Healthcare Research and Quality.

DATES: The meeting will be held on Wednesday, July 12, 2023, from 11:15 
a.m. to 3:30 p.m.

ADDRESSES: The meeting will be held virtually.

FOR FURTHER INFORMATION CONTACT: Jaime Zimmerman, Designated Management 
Official, at the Agency for Healthcare Research and Quality, 5600 
Fishers Lane, Mail Stop 06E37A, Rockville, Maryland 20857, (301) 427-
1456. For press-related information, please contact Bruce Seeman at 
(301) 427-1998 or [email protected].
    Closed captioning will be provided during the meeting. If another 
reasonable accommodation for a disability is needed, please contact the 
Food and Drug Administration (FDA) Office of Equal Employment 
Opportunity and Diversity Management on (301) 827-4840, no later than 
Wednesday, May 31, 2023. The agenda, roster, and minutes will be 
available from Jenny Griffith, Committee Management Officer, Agency for 
Healthcare Research and Quality, 5600 Fishers Lane, Rockville, Maryland 
20857. Jenny Griffith's phone number is (240) 446-6799.

SUPPLEMENTARY INFORMATION:

I. Purpose

    In accordance with the Federal Advisory Committee Act, this notice 
announces a meeting of the National Advisory Council for Healthcare 
Research and Quality (the Council). 5 U.S.C. 1009. The Council is 
authorized by section 941 of the Public Health Service Act, 42 U.S.C. 
299c. In accordance with its statutory mandate, the Council is to 
advise the Secretary of the Department of Health and Human Services and 
the Director of AHRQ on matters related to AHRQ's conduct of its 
mission including providing guidance on (A) priorities for health care 
research, (B) the field of health care research including training 
needs and information dissemination on health care quality and (C) the 
role of the Agency in light of private sector activity and 
opportunities for public private partnerships. The Council is composed 
of members of the public, appointed by the Secretary, and Federal ex-
officio members specified in the authorizing legislation.

II. Agenda

    On Wednesday, July 12, 2023, NAC members will meet to conduct 
preparatory work prior to convening the Council meeting at 11:15 a.m., 
with the call to order by the Council Chair, an introduction of NAC 
members, and approval of previous Council summary notes. The NAC 
members will then receive an update from the AHRQ Director. The agenda 
will also include an update on AHRQ's aging initiatives and a 
discussion of consumer experience measurements. The meeting is open to 
the public and will adjourn at 3:30 p.m. For information regarding how 
to access the meeting as well as other meeting details, including 
information on how to make a public comment, please go to https://www.ahrq.gov/news/events/nac/. The

[[Page 30747]]

final agenda will be available on the AHRQ website no later than 
Wednesday, June 28, 2023.

    Dated: May 8, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023-10140 Filed 5-11-23; 8:45 am]
BILLING CODE 4160-90-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.